Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
February 25 2021 - 8:00AM
Business Wire
Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will report fourth
quarter and year end financial results on Thursday, March 11, 2021.
Following distribution of the earnings release via wire services,
the Ocular Therapeutix management team will host a live conference
call and webcast at 4:30 p.m. Eastern Time to review the Company’s
financial results and provide a general business update.
The live webcast can be accessed by visiting the Investors
section of the Company’s website at investors.ocutx.com. Please
connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to
access the webcast. Alternatively, please call (844) 464-3934
(U.S.) or (765) 507-2620 (International) to listen to the live
conference call. The conference ID number for the live call will be
7189257. An archive of the webcast will be available until June 10,
2021 on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA, is FDA-approved for the treatment of ocular inflammation
and pain following ophthalmic surgery. Ocular Therapeutix has also
submitted a Supplemental NDA for DEXTENZA to include the treatment
of ocular itching associated with allergic conjunctivitis as an
additional approved indication. Ocular Therapeutix’s earlier stage
development assets currently in Phase 1 clinical trials include
OTX-TKI (axitinib intravitreal implant) for the treatment of wet
AMD and other retinal diseases and OTX-TIC (travoprost intracameral
implant) for the reduction of intraocular pressure in patients with
primary open-angle glaucoma or ocular hypertension. Ocular
Therapeutix is currently evaluating OTX-CSI (cyclosporine
intracanalicular insert) for the treatment of dry eye disease in a
Phase 2 clinical trial. Also, Ocular Therapeutix has recently filed
a Phase 2-enabling investigational new drug application for OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease. Also, in
collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal
injection) is in pre-clinical development as an extended-delivery
formulation of aflibercept for the treatment of retinal diseases.
Ocular Therapeutix's first product, ReSure® Sealant is an FDA
approved device to prevent wound leaks in corneal incisions
following cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005272/en/
Investors Ocular Therapeutix Donald Notman Chief Financial
Officer dnotman@ocutx.com
or
Westwicke Partners Chris Brinzey Managing Director
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice President,
Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024